A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder - Long-Term Extension Of Study SCA104779 - - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder - Long-Term Extension Of Study SCA104779 -

This study is currently recruiting participants.

Study NCT00566020. Last updated on November 19, 2008. Information provided by GlaxoSmithKline

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields

Brief Title ^†

A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder - Long-Term Extension Of Study SCA104779 -

Official Title ^†

Study SCA106052, a Clinical Evaluation of BW430C (Lamotrigine) in Bipolar I Disorder - Long-Term Extension Study (Extension of Study SCA104779) -

Brief Summary

This study is planned to assess the long-term safety of lamotrigine in Japanese patients with bipolar I disorder who will continue into the 52-week extension upon completion of a double-blind comparative study (Study No.: SCA104779), i.e. the patients who receive the addition of any additional treatment to intervene in a mood episode in the double-blind phase or the patients completing the double-blind phase.

Detailed Description

Study Phase

Phase III

Study Type ^†

Interventional

Study Design ^†

Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety Study

Primary Outcome Measure ^†

- Adverse events at every visit - Abnormality of clinical laboratory test values at Week0, Week6, Week16, Week28, Week 40 and Week 52 - Vital signs at every visit - Electrocardiogram at Week0, Week6, Week28 and Week 52

Secondary Outcome Measure ^†

- CGI-S at every visit - HAM-D at Week0, Week6, Week16, Week28, Week 40 and Week 52 - YMRS at Week0, Week6, Week16, Week28, Week 40 and Week 52 - Serum lamotrigine concentrations at Week6, Week16, Week28, Week 40 and Week 52 [ Time Frame: Week 52 ]
Change from baseline of Clinical Global Impressions of Severity (CGI-S); Change from baseline of Hamilton Depression Rating Scale (HAM-D); Change from baseline of Young Mania Rating Scale (YMRS);

Condition ^†

Bipolar Disorder

Intervention ^†

Drug: BW430C (lamotrigine)

MEDLINE PMIDs

Links

Recruitment Information Fields

Recruitment Status ^†

Recruiting

Enrollment ^†

Start Date ^†

May 2008

Completion Date

December 2010

Eligibility Criteria ^†

Inclusion Criteria:

Of subjects participating in the preceding double-blind study, those who are judged by the investigator/sub-investigator to have well tolerated the double-blind treatment and to be eligible for the 52-week extension treatment
Sex: either sex. Female of child-bearing potential will be eligible for inclusion in this study. However they have to have a negative pregnancy test at the start of this study, agree to further pregnancy testing at the time points determined in study assessments and procedures and practice one of the following methods of contraception from the start of this study until the end of the follow-up examination:

Abstinence

Oral contraceptive, either combined or progestogen alone (except during the Dosage Adjustment Phase)

Injectable progestogen

Implants of levonorgestrel

Estrogenic vaginal ring (except during the Dosage Adjustment Phase)

Percutaneous contraceptive patches (except during the Dosage Adjustment Phase)

Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP effectiveness criteria as stated in the product label

Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject

Double barrier method: condom or occlusive cap (diaphragm or cervical / vault caps) plus spermicidal agent (foam / gel / film / cream / suppository)

In/Out patient: Either
Informed consent: the subject capable of giving written informed consent

Exclusion Criteria:

Has a score of 3 or more on item of the HAM-D related to suicide or is at a high suicidal risk in the judgment of the investigator/sub-investigator
Has a history of severe rash or rash due to anti-epileptic drugs
Patients with severe hepatic/renal/cardiac/pulmonary disorder or hematopoietic disorder. The severity refers to Grade 3 according to "the Classification of the Severity of Adverse Experiences" (PAB/SD Notification No. 80, dated 29 June 1992)
Patients have less than 5 years of remission history from clinically significant malignancy (other than e.g. basal cell or squamous cell skin cancer, in-situ carcinoma of cervix or prostate CA in situ)
Patients with chronic hepatitis typeB and /or typeC which is positive of hepatitis B surface antigen （HBsAg）and/or hepatitis C antibody
Has an acute or chronic illness likely to impair drug absorption, distribution, metabolism or excretion or has any unstable physical symptoms likely to require hospitalisation during participation in the study
Female patients who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study
Has a history or current diagnosis of epilepsy
Has received an investigational drug within 30 days of screening
Patients with a history of drug allergy to any ingredient of the test-drug
Patients whom the investigator or sub-investigator considers ineligible for the study

Gender

Both

Ages

20 Years and older

Accepts Healthy Volunteers

Contacts ^††

Contact: US GSK Clinical Trials Call Center

877-379-3718

Location Countries ^†

Japan

Administrative Information Fields

NCT ID ^†

NCT00566020

Organization ID

SCA106052

Secondary IDs ^††

Study Sponsor ^†

GlaxoSmithKline

Collaborators ^††

Investigators ^†

Study Director:

GSK Clinical Trials, MD

GlaxoSmithKline

Information Provided By

GlaxoSmithKline

Verification Date

November 2008

First Received Date ^†

November 28, 2007

Last Updated Date

November 19, 2008

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.